US 11813359
Sustained release olanzapine formulations
granted A61KA61K31/551A61K31/5513
Quick answer
US patent 11813359 (Sustained release olanzapine formulations) held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Grant date
- Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K31/551, A61K31/5513, A61K47/34, A61K9/0019